Insulin Pricing Measure Delayed as Congress Awaits Cost Estimate

Legislation to reduce what Americans pay for insulin will likely have to wait until after the Memorial Day recess as lawmakers supporting the bill await a forecast on how it would affect federal deficits and spending.

Sens. Susan Collins (R-Maine) and Jeanne Shaheen (D-N.H.) said they’re waiting for a score from the nonpartisan Congressional Budget Office on their bill aimed at lowering the price of insulin and capping what patients pay for the crucial diabetes medicine. Eli Lilly & Co., Novo Nordisk A/S, and Sanofi are three of the largest drugmakers in the space.

Collins said she’s “encouraged that we’re ...